Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Trevena Inc is a biotechnology business based in the US. Trevena shares (TRVN) are listed on the NASDAQ and all prices are listed in US Dollars. Trevena employs 43 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.39 |
|---|---|
| 52-week range | $0.18 - $1.70 |
| 50-day moving average | $0.33 |
| 200-day moving average | $0.62 |
| Wall St. target price | $3.17 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.35 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.39 from 2022-07-01
| 1 week (2022-06-28) | -5.48% |
|---|---|
| 1 month (2022-06-03) | 9.49% |
| 3 months (2022-04-05) | -15.05% |
| 6 months (2022-01-01) | N/A |
| 1 year (2021-07-02) | -76.79% |
|---|---|
| 2 years (2020-07-02) | -74.51% |
| 3 years (2019-07-05) | 1.03 |
| 5 years (2017-07-05) | 2.38 |
| Revenue TTM | $378,000 |
|---|---|
| Gross profit TTM | $-387,000 |
| Return on assets TTM | -39.98% |
| Return on equity TTM | -78.85% |
| Profit margin | 0% |
| Book value | $0.30 |
| Market capitalisation | $64.6 million |
TTM: trailing 12 months
We're not expecting Trevena to pay a dividend over the next 12 months.
Over the last 12 months, Trevena's shares have ranged in value from as little as $0.181 up to $1.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trevena's is 2.4419. This would suggest that Trevena's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Trevena, Inc. , a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.